These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. Maher AR; Theodore G J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311 [TBL] [Abstract][Full Text] [Related]
4. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Ketter TA; Nasrallah HA; Fagiolini A Psychopharmacol Bull; 2006; 39(1):120-46. PubMed ID: 17065977 [TBL] [Abstract][Full Text] [Related]
5. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Perlis RH Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. Vieta E; Valentà M CNS Drugs; 2013 Jul; 27(7):515-29. PubMed ID: 23749421 [TBL] [Abstract][Full Text] [Related]
7. Managing bipolar disorder in the elderly: defining the role of the newer agents. Sajatovic M; Madhusoodanan S; Coconcea N Drugs Aging; 2005; 22(1):39-54. PubMed ID: 15663348 [TBL] [Abstract][Full Text] [Related]
8. Safety considerations in the psychopharmacology of pediatric bipolar disorder. Sun AY; Woods S; Findling RL; Stepanova E Expert Opin Drug Saf; 2019 Sep; 18(9):777-794. PubMed ID: 31242784 [No Abstract] [Full Text] [Related]
9. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Dunner DL Bipolar Disord; 2005 Aug; 7(4):307-25. PubMed ID: 16026484 [TBL] [Abstract][Full Text] [Related]
14. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Jing Y; Kim E; You M; Pikalov A; Tran QV J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195 [TBL] [Abstract][Full Text] [Related]
15. [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Moreno RA; Moreno DH; Soares MB; Ratzke R Braz J Psychiatry; 2004 Oct; 26 Suppl 3():37-43. PubMed ID: 15597138 [TBL] [Abstract][Full Text] [Related]
16. Bipolar disorder in adolescence. DeFilippis M; Wagner KD Adolesc Med State Art Rev; 2013 Aug; 24(2):433-45, ix. PubMed ID: 24298757 [TBL] [Abstract][Full Text] [Related]
17. Evaluating drug safety in children and adolescents with bipolar disorder. Heaton PC; Garlick CM; Tran D Curr Drug Saf; 2006 Aug; 1(3):307-18. PubMed ID: 18690942 [TBL] [Abstract][Full Text] [Related]
18. New treatments for bipolar disorder: the role of atypical neuroleptic agents. Ghaemi SN J Clin Psychiatry; 2000; 61 Suppl 14():33-42. PubMed ID: 11154015 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacotherapy in bipolar disorders during childhood and adolescence]. Vloet JA; Hagenah UF Z Kinder Jugendpsychiatr Psychother; 2009 Jan; 37(1):27-49, quiz 49-50. PubMed ID: 19105162 [TBL] [Abstract][Full Text] [Related]
20. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review]. Munch G; Godart N Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]